Overview

A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder

Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if TC-5214 or placebo (a tablet that looks like medicine tablet or capsule, but contains no active medicine) is safe and effective when taken for 52 weeks with another antidepressant medicine.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Collaborator:
Targacept Inc.
Treatments:
Serotonin
Serotonin Uptake Inhibitors